Drug Profile
Olpasiran - Amgen
Alternative Names: AMG-890; ARC LPA; ARO LPA; RNAi ARC-LPALatest Information Update: 11 Feb 2024
Price :
$50
*
At a glance
- Originator Arrowhead Pharmaceuticals
- Developer Amgen
- Class Cardiovascular therapies; Small interfering RNA
- Mechanism of Action Lipoprotein A expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Cardiovascular disorders
Most Recent Events
- 01 Feb 2024 Phase-III clinical trials in Cardiovascular disorders in Iceland, Netherlands, Argentina, Hong Kong, Argentina, Austria, Belgium, Brazil, Bulgaria, China, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Mexico, Lithuania, Norway, Portugal, Poland, Romania, Slovakia, Slovakia, South Korea, Spain, Sweden, Taiwan, United Kingdom (SC) (NCT05581303)
- 19 Dec 2023 Amgen completes a phase I pharmacokinetics, safety and pharmacodynamics trial for Hepatic Impairment in USA (SC, Injection) (NCT05489614)
- 11 Nov 2023 Efficacy data from a phase-II OCEAN(a)-DOSE trial in Cardiovascular presented at the American Heart Association Scientific Sessions 2023 (AHA-2023)